Modak Joyanta K, Liu Yu C, Supuran Claudiu T, Roujeinikova Anna
Department of Microbiology, Monash University , Clayton, Victoria 3800, Australia.
Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University , Clayton, Victoria 3800, Australia.
J Med Chem. 2016 Dec 22;59(24):11098-11109. doi: 10.1021/acs.jmedchem.6b01333. Epub 2016 Dec 8.
α-Carbonic anhydrase of Helicobacter pylori (HpαCA) plays an important role in the acclimation of this oncobacterium to the acidic pH of the stomach. Sulfonamide inhibitors of HpαCA possess anti-H. pylori activity. The crystal structures of complexes of HpαCA with a family of acetazolamide-related sulfonamides have been determined. Analysis of the structures revealed that the mode of sulfonamide binding correlates well with their inhibitory activities. In addition, comparisons with the corresponding inhibitor complexes of human carbonic anhydrase II (HCAII) indicated that HpαCA possesses an additional, alternative binding site for sulfonamides that is not present in HCAII. Furthermore, the hydrophobic pocket in HCAII that stabilizes the apolar moiety of sulfonamide inhibitors is replaced with a more open, hydrophilic pocket in HpαCA. Thus, our analysis identified major structural features can be exploited in the design of selective and more potent inhibitors of HpαCA that may lead to novel antimicrobials.
幽门螺杆菌的α-碳酸酐酶(HpαCA)在这种致癌细菌适应胃部酸性pH环境中起着重要作用。HpαCA的磺胺类抑制剂具有抗幽门螺杆菌活性。已确定HpαCA与一类乙酰唑胺相关磺胺类化合物复合物的晶体结构。结构分析表明,磺胺类药物的结合模式与其抑制活性密切相关。此外,与人碳酸酐酶II(HCAII)相应抑制剂复合物的比较表明,HpαCA具有一个HCAII中不存在的额外磺胺类药物替代结合位点。此外,HCAII中稳定磺胺类抑制剂非极性部分的疏水口袋在HpαCA中被一个更开放的亲水口袋所取代。因此,我们的分析确定了在设计可能导致新型抗菌药物的HpαCA选择性更强的抑制剂时可以利用的主要结构特征。